Eswatini vs Senegal: Access to anti-retroviral drugs, female
Eswatini
98.0%
in 2024
Senegal
98.0%
in 2024
Eswatini rank
1st
Senegal rank
1st
Access to anti-retroviral drugs, female over time
- Eswatini
- Senegal
How they compare
Eswatini currently reports 98.0% against 98.0% in Senegal, a difference of 0.0%.
The two have swapped places 6 times across 25 shared years of data; in 2000 it was Senegal ahead.
Eswatini ranks 1st and Senegal ranks 1st of 141 countries.
Across the 3 decades both report, Eswatini averaged higher in 2 and Senegal in 1.
Head to head by decade
| Decade | Eswatini | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 7.7% | 10.6% | 2.9% | Senegal |
| 2010s | 64.4% | 62.8% | 1.6% | Eswatini |
| 2020s | 97.4% | 95.0% | 2.4% | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Eswatini or Senegal?
- Eswatini, at 98.0% against 98.0% in Senegal as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Eswatini and Senegal?
- 0.0%, with Eswatini ahead.
- How many years of comparable data are there for Eswatini and Senegal?
- 25 years are reported by both, from 2000 to 2024.
- How do Eswatini and Senegal rank globally for access to anti-retroviral drugs, female?
- Eswatini ranks 1st and Senegal ranks 1st of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.